Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

3.49USD
17 Feb 2017
Change (% chg)

$-0.03 (-0.85%)
Prev Close
$3.52
Open
$3.49
Day's High
$3.54
Day's Low
$3.46
Volume
301,842
Avg. Vol
480,277
52-wk High
$8.73
52-wk Low
$2.86

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock
Thursday, 26 Jan 2017 04:29pm EST 

Celldex Therapeutics Inc :Files for offering of up to 18.4 million shares of common stock by the selling stockholders.  Full Article

Celldex reports second quarter 2016 results
Monday, 8 Aug 2016 04:01pm EDT 

Celldex Therapeutics Inc : Q2 revenue $1.4 million versus $2.7 million . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex reports second quarter 2016 results . Q2 loss per share $0.32 .Q2 revenue view $850,000 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics initiates phase 1/2 study of Varlilumab in combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
Thursday, 28 May 2015 09:23am EDT 

Celldex Therapeutics:Says initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib (SUTENT) in patients with metastatic clear cell renal cell carcinoma (CC-RCC).Varlilumab is Celldex's fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade.Sunitinib is approved by the FDA as monotherapy for the treatment of advanced renal cell carcinoma (RCC), as well as certain advanced gastrointestinal stromal tumors and pancreatic neuroendocrine tumors.Varlilumab is currently being studied in four Phase 1/2 combination studies, and additional combination studies will be initiated in 2015.  Full Article

Celldex Therapeutics announces initiation of phase 1/2 study of varlilumab in combination with ipilimumab and CDX-1401 in metastatic melanoma
Monday, 6 Apr 2015 08:01am EDT 

Celldex Therapeutics Inc:Announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and ipilimumab (Yervoy(); Bristol-Myers Squibb) in patients with Stage III or IV metastatic melanoma.Varlilumab is Celldex's fully human monoclonal antibody that targets CD27, a critical co-stimulatory molecule in the immune activation cascade.Ipilimumab, a recombinant, human monoclonal antibody that blocks CTLA-4, is FDA approved for the treatment of unresectable or metastatic melanoma.In the Phase 2 portion of the study, patients with tumors that express NY-ESO-1 will also receive CDX-1401, Celldex's off-the-shelf antibody-based dendritic cell vaccine that targets tumors expressing the NY-ESO-1 oncoprotein.  Full Article

Celldex Therapeutics, Inc announces clinical trial collaboration with Roche to Evaluate Combination of Varlilumab and MPDL3280A
Tuesday, 17 Mar 2015 08:01am EDT 

Celldex Therapeutics, Inc:Enters into clinical trial collaboration with Roche to evaluate safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1).Says Varlilumab and MPDL3280A are part of new class of investigational medicines known as cancer immunotherapies.Says these are designed to harness body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease.Under terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.  Full Article

More From Around the Web

BRIEF-COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016

* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2lwtvZF) Further company coverage: